Ibodutant (Irritable Bowel Syndrome) Market Forecast - Opportunities, Trends and Challenges to 2023

Ibodutant (Irritable Bowel Syndrome) Market Size, Share, Trends, Company

Profiles, Demand, Insights, Analysis, Research, Report, Opportunities,

Segmentation and Forecast To 2023

Summary

Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort

associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a

considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a

large, albeit naive, one, with only a small number of pharmacotherapies indicated for the

treatment of the disorder, and it is also characterized by significant unmet needs.

Ibodutant is being developed by Menarini for the treatment of women with IBS-D. The Phase III

program for ibodutant was initiated in Q1 2014 with two Phase III clinical trials, a 12-week

study and a 52-week study, both of which were designed to evaluate the efficacy and safety of

this product (Menarini, NCT02107196; Menarini, NCT02120027).

Scope

- Overview of IBS, including epidemiology, etiology, symptoms, diagnosis, pathology and

treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Ibodutant including product description, safety and efficacy profiles as

well as a SWOT analysis.

- Sales forecast for Ibodutant for the top 7 countries from 2013 to 2023.

- Sales information covered for the US, France, Germany, Italy, Spain, UK and Japan.

Enquire About Report: http://www.radiantinsights.com/research/ibodutant-irritablebowel-syndrome-forecast-and-market-analysis-to-2023

Reasons To Buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.

- Stay ahead of the competition by understanding the changing competitive landscape for IBS.

- Effectively plan your M&A and partnership strategies by identifying drugs with the most

promising sales potential.

- Make more informed business decisions from insightful and in-depth analysis of Ibodutant

performance....